141 related articles for article (PubMed ID: 34865874)
1. Human papillomavirus vaccines effectiveness to prevent genital warts: A population-based study using health system integrated databases, 2009-2017.
Muñoz-Quiles C; López-Lacort M; Díez-Domingo J; Rodrigo-Casares V; Orrico-Sánchez A
Vaccine; 2022 Jan; 40(2):316-324. PubMed ID: 34865874
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness of HPV vaccines against genital warts in women from Valencia, Spain.
Navarro-Illana E; López-Lacort M; Navarro-Illana P; Vilata JJ; Diez-Domingo J
Vaccine; 2017 Jun; 35(25):3342-3346. PubMed ID: 28499554
[TBL] [Abstract][Full Text] [Related]
3. Quadrivalent human papillomavirus vaccine effectiveness: a Swedish national cohort study.
Leval A; Herweijer E; Ploner A; Eloranta S; Fridman Simard J; Dillner J; Young C; Netterlid E; Sparén P; Arnheim-Dahlström L
J Natl Cancer Inst; 2013 Apr; 105(7):469-74. PubMed ID: 23486550
[TBL] [Abstract][Full Text] [Related]
4. Association of varying number of doses of quadrivalent human papillomavirus vaccine with incidence of condyloma.
Herweijer E; Leval A; Ploner A; Eloranta S; Simard JF; Dillner J; Netterlid E; Sparén P; Arnheim-Dahlström L
JAMA; 2014 Feb; 311(6):597-603. PubMed ID: 24519299
[TBL] [Abstract][Full Text] [Related]
5. Evaluating the Early Benefit of Quadrivalent HPV Vaccine on Genital Warts in Belgium: A Cohort Study.
Dominiak-Felden G; Gobbo C; Simondon F
PLoS One; 2015; 10(7):e0132404. PubMed ID: 26147096
[TBL] [Abstract][Full Text] [Related]
6. Modeling the impact of the difference in cross-protection data between a human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and a human papillomavirus (HPV)-6/11/16/18 vaccine in Canada.
Kohli M; Lawrence D; Haig J; Anonychuk A; Demarteau N
BMC Public Health; 2012 Oct; 12():872. PubMed ID: 23061913
[TBL] [Abstract][Full Text] [Related]
7. Quadrivalent HPV vaccine effectiveness against anogenital warts: A registry-based study of 2,2 million individuals.
Nygård S; Nygård M; Orumaa M; Hansen BT
Vaccine; 2023 Aug; 41(37):5469-5476. PubMed ID: 37516572
[TBL] [Abstract][Full Text] [Related]
8. The quadrivalent HPV vaccine is protective against genital warts: a meta-analysis.
Lukács A; Máté Z; Farkas N; Mikó A; Tenk J; Hegyi P; Németh B; Czumbel LM; Wuttapon S; Kiss I; Gyöngyi Z; Varga G; Rumbus Z; Szabó A
BMC Public Health; 2020 May; 20(1):691. PubMed ID: 32460747
[TBL] [Abstract][Full Text] [Related]
9. Inclusion of the benefits of enhanced cross-protection against cervical cancer and prevention of genital warts in the cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands.
Westra TA; Stirbu-Wagner I; Dorsman S; Tutuhatunewa ED; de Vrij EL; Nijman HW; Daemen T; Wilschut JC; Postma MJ
BMC Infect Dis; 2013 Feb; 13():75. PubMed ID: 23390964
[TBL] [Abstract][Full Text] [Related]
10. HPV vaccination leads to decrease of anogenital warts and precancerous lesions of the cervix uteri in young women with low vaccination rates: a retrospective cohort analysis.
Osmani V; Fett S; Tauscher M; Donnachie E; Schneider A; Klug SJ
BMC Cancer; 2022 Dec; 22(1):1293. PubMed ID: 36494790
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of different human papillomavirus vaccines in Singapore.
Lee VJ; Tay SK; Teoh YL; Tok MY
BMC Public Health; 2011 Mar; 11():203. PubMed ID: 21453537
[TBL] [Abstract][Full Text] [Related]
12. One-Dose Human Papillomavirus Vaccination and the Risk of Genital Warts: A Danish Nationwide Population-based Study.
Baandrup L; Dehlendorff C; Kjaer SK
Clin Infect Dis; 2021 Nov; 73(9):e3220-e3226. PubMed ID: 33048118
[TBL] [Abstract][Full Text] [Related]
13. Health economic evaluation of Human Papillomavirus vaccines in women from Venezuela by a lifetime Markov cohort model.
Bardach AE; Garay OU; Calderón M; Pichón-Riviére A; Augustovski F; Martí SG; Cortiñas P; Gonzalez M; Naranjo LT; Gomez JA; Caporale JE
BMC Public Health; 2017 Feb; 17(1):152. PubMed ID: 28148228
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of HPV vaccination in the context of high cervical cancer incidence and low screening coverage.
Võrno T; Lutsar K; Uusküla A; Padrik L; Raud T; Reile R; Nahkur O; Kiivet RA
Vaccine; 2017 Nov; 35(46):6329-6335. PubMed ID: 28899625
[TBL] [Abstract][Full Text] [Related]
15. No evidence for cross-protection of the HPV-16/18 vaccine against HPV-6/11 positivity in female STI clinic visitors.
Woestenberg PJ; King AJ; van der Sande MA; Donken R; Leussink S; van der Klis FR; Hoebe CJ; Bogaards JA; van Benthem BH; ;
J Infect; 2017 Apr; 74(4):393-400. PubMed ID: 28126492
[TBL] [Abstract][Full Text] [Related]
16. Quadrivalent human papillomavirus vaccination and trends in genital warts in Australia: analysis of national sentinel surveillance data.
Donovan B; Franklin N; Guy R; Grulich AE; Regan DG; Ali H; Wand H; Fairley CK
Lancet Infect Dis; 2011 Jan; 11(1):39-44. PubMed ID: 21067976
[TBL] [Abstract][Full Text] [Related]
17. Dose-Related Differences in Effectiveness of Human Papillomavirus Vaccination Against Genital Warts: A Nationwide Study of 550,000 Young Girls.
Blomberg M; Dehlendorff C; Sand C; Kjaer SK
Clin Infect Dis; 2015 Sep; 61(5):676-82. PubMed ID: 25944340
[TBL] [Abstract][Full Text] [Related]
18. Impact of quadrivalent human papillomavirus vaccine on genital warts in an opportunistic vaccination structure.
Lurie S; Mizrachi Y; Chodick G; Katz R; Schejter E
Gynecol Oncol; 2017 Aug; 146(2):299-304. PubMed ID: 28602548
[TBL] [Abstract][Full Text] [Related]
19. Spotlight on quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine(Gardasil®) in the prevention of premalignant genital lesions, genital cancer, and genital warts in women.
McCormack PL; Joura EA
BioDrugs; 2011 Oct; 25(5):339-43. PubMed ID: 21942919
[TBL] [Abstract][Full Text] [Related]
20. Potential impact of the human papillomavirus vaccine on the incidence proportion of genital warts in French women (EFFICAE study): a multicentric prospective observational study.
Judlin P; Jacquard AC; Carcopino X; Aubin F; Dahlab A; Mistretta F; Not D; Boelle PY; Aynaud O; Soubeyrand B
Sex Health; 2016 Feb; 13(1):49-54. PubMed ID: 26567557
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]